Modular hinged megaprosthesis after wide resection or massive bone loss | advanced
Surgical Imaging
Location: The popliteal artery and vein lie directly posterior to the distal femoral metaphysis; the sciatic nerve divides into tibial and common peroneal branches at the upper border of the popliteal fossa.
Risk: During posterior capsular release or tumour mobilisation the vessels can be lacerated or stretched; nerve injury causes foot drop or complete paralysis. Identify both structures early, loop them with vessel loops, and keep them under direct vision throughout the resection.
Location: The patellar tendon inserts on the tibial tubercle and must be preserved or reconstructed; the quadriceps tendon and vastus medialis are mobilised with the approach.
Risk: Detachment or devascularisation of the patellar tendon leads to permanent extensor lag and poor function. In tumour cases the tendon may need to be tenodesed to the prosthesis flange or augmented with synthetic mesh (Trevira). Tension the repair so that the knee can be flexed to 90 degrees without excessive pull on the suture line.
Location: The medial and lateral collateral ligaments attach to the epicondyles; in a distal femoral replacement they are usually sacrificed with the resection.
Risk: The rotating-hinge mechanism compensates for ligament loss, but if the hinge is malrotated or the tibial component is internally rotated the knee will have persistent instability or patellar maltracking. Confirm rotation with the tibial tubercle and epicondylar axis before cementing.
Location: Preoperative MRI defines the intramedullary extent; the resection must achieve at least 2 cm of normal marrow beyond the tumour signal on T2-weighted sequences.
Risk: Positive marrow margin leads to local recurrence. Always send a 1 cm marrow margin for frozen section before completing the osteotomy. If positive, resect an additional 2 cm and repeat the frozen section.
Location: Megaprostheses have large metal surface area and are at high risk of early deep infection, especially in the first 3 months.
Risk: Infection rates exceed 10 percent in most published series. Use dual antibiotic prophylaxis (cefazolin plus vancomycin or teicoplanin), antibiotic-loaded cement when stems are cemented, and consider silver-coated implants in high-risk patients. Any wound ooze after 48 hours warrants aspiration and culture.
Location: Stress riser at the junction between the stiff megaprosthesis stem and the native diaphyseal bone.
Risk: Fracture occurs with minor trauma or during stem insertion if the canal is over-reamed or under-reamed. Choose stem diameter to achieve 2-3 mm cement mantle (cemented) or tight press-fit (uncemented); consider prophylactic cerclage cables at the stem tip in osteopenic bone.
M.E.G.A.P.R.OMEGAPROSTHESIS — Operative Sequence
F.I.X.A.T.I.O.NFIXATION — Cemented versus Uncemented/Compress
C.O.M.P.L.I.CCOMPLICATIONS — Megaprosthesis Failure Modes
Surgical Indications
Oncologic Indications
- Primary malignant bone tumours of the distal femur (osteosarcoma, Ewing sarcoma, chondrosarcoma) in patients with no metastatic disease and resectable lesion with adequate margins
- Metastatic disease with solitary or oligometastatic lesions causing catastrophic bone loss or impending fracture when curettage and augmentation are not feasible
- Failed limb-salvage reconstruction with massive allograft or previous megaprosthesis requiring revision
Non-Oncologic Indications
- Catastrophic periprosthetic distal femoral fracture or bone loss after total knee arthroplasty where conventional revision implants cannot achieve stable fixation
- Non-reconstructable distal femoral bone loss from infection, osteolysis, or multiple failed revisions
- Severe distal femoral deformity or non-union with bone loss exceeding 5 cm
Contraindications
Absolute:
- Active deep infection at the site (must be eradicated first)
- Inadequate soft-tissue envelope for coverage (requires plastic surgery input)
- Patient unable to comply with postoperative weight-bearing or surveillance
Relative:
- Skeletally immature patients (consider expandable prosthesis or rotationplasty)
- Poor expected survival (less than 6 months) where palliative stabilisation may suffice
- Severe peripheral vascular disease precluding safe tourniquet use or vessel mobilisation
Evidence Base
Oncologic Outcomes
Wide resection with megaprosthesis reconstruction achieves local control rates of 85-95 percent at 5 years when negative margins are obtained. Overall survival depends on histologic grade and response to neoadjuvant chemotherapy rather than the reconstruction itself. Limb salvage is possible in greater than 90 percent of distal femoral sarcomas with modern techniques.
Functional Outcomes
Rotating-hinge megaprostheses restore knee range of motion averaging 90-110 degrees. Extensor lag is the most important determinant of function; patients with lag less than 10 degrees achieve near-normal gait. Musculoskeletal Tumour Society (MSTS) scores average 70-85 percent of normal in long-term survivors.
Implant Survival
Cemented modular megaprostheses demonstrate 70-80 percent survival at 10 years and 50-60 percent at 20 years. Aseptic loosening and infection are the dominant failure modes. Compress (force-directed) fixation with porous collar shows improved 10-year survival (greater than 85 percent) in selected young patients with good bone stock.
Cemented versus Compress Fixation — Evidence Summary
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“A 22-year-old man presents with a distal femoral osteosarcoma. MRI shows the tumour extending to within 1 cm of the physis with no skip lesions. Staging CT chest and bone scan are negative. How do you plan the resection and reconstruction?”
“A 68-year-old woman with a previous distal femoral replacement for sarcoma now has catastrophic loosening of the femoral stem with 8 cm of bone loss and a periprosthetic fracture. She has no evidence of recurrence. How do you revise her reconstruction?”
“You are planning a distal femoral megaprosthesis in a 35-year-old man with a high-grade osteosarcoma. He asks about the risk of infection and whether a silver-coated implant would be beneficial. How do you counsel him?”